Daily AI Briefing — March 10, 2026

The dominant story this week is Anthropic's escalating legal battle with the Department of Defense over its designation as a 'supply chain risk,' stemming from the company's refusal to allow Claude to be used for mass surveillance or autonomous weapons. The clash has drawn unprecedented industry support, with OpenAI and Google DeepMind employees—including chief scientist Jeff Dean—filing an amicus brief in Anthropic's defense. Anthropic warns the fallout could cost it billions in paused deals.

In product and platform news:

• Nvidia is preparing an open-source AI agent platform ahead of its developer conference
• Microsoft is deepening Claude integration across Copilot while expanding agentic AI features
• OpenAI launched Codex Security for automated vulnerability detection; Anthropic countered with Code Review in Claude Code
• Andrej Karpathy open-sourced Autoresearch, a lightweight tool for autonomous ML experimentation

On the infrastructure and funding front, UK startup Nscale raised $2B at a $14.6B valuation with Sheryl Sandberg and Nick Clegg joining its board, even as a Guardian investigation revealed many of the UK's announced AI investments remain undelivered 'phantom investments.' The UK also announced a £500M sovereign AI fund launching in April.

A strong day for AI safety and alignment research, with multiple papers exposing cracks in core assumptions behind current safety strategies.

• The CoT-Control evaluation suite reveals reasoning models cannot reliably control their chain-of-thought, directly threatening the viability of CoT monitoring as a safety mechanism
• Choice blindness experiments show 91% of surreptitiously swapped RLHF preferences go undetected by human annotators, undermining a foundational assumption of alignment-from-human-feedback
• Countdown-Code provides a minimal testbed for precisely measuring reward hacking emergence in RLVR, while a separate audit finds LLM-as-Judge safety evaluations perform near coin-flip reliability under adversarial distribution shifts
• The Disentangled Safety Hypothesis identifies separate Recognition and Execution axes governing LLM safety behavior, offering new mechanistic understanding

On the training and inference scaling front, a comprehensive taxonomy of Unsupervised RLVR methods maps how far RL post-training can scale without supervised data. A rigorous Sequential Monte Carlo analysis of parallel inference-time reasoning establishes theoretical foundations for pass@k and related strategies, while a complementary negative result shows consensus-based scaling fails to improve LLM truthfulness across five benchmarks.

• Anthropic's lawsuit against the US Department of War over military deployment of Claude marks a landmark AI governance event
• Google's AMIE diagnostic AI reports a prospective clinical feasibility study with 100 real patients in primary care

Andrej Karpathy's autoresearch experiment dominated the AI conversation — an autonomous agent found ~20 improvements to nanochat over two days, cutting 'Time to GPT-2' by 11%. This sparked broad discussion about AI self-improvement loops, with Harrison Chase (LangChain) building an "autoresearch for agents" variant.

• Anthropic shipped Claude Code Review, a multi-agent PR review system; engineer bcherny reported 200% productivity gains and explained how separate context windows make subagent review effective
• Anthropic filed two lawsuits against the US government alleging retaliation for refusing to remove Claude's restrictions on autonomous lethal warfare — a major AI policy flashpoint
• OpenAI announced acquiring Promptfoo for agentic security testing, while Andrew Ng launched Context Hub to combat coding agents hallucinating outdated API docs

A strong contrarian thread emerged around agent reliability: svpino's viral post declaring "these agents don't work as promised" drew 668K views and resurfaced concrete failures from Chevrolet, Air Canada, and others. Ethan Mollick noted that six weeks after Claude Cowork launched, no competitor has emerged — a telling signal about the gap between lab claims and shipped products.